

Proceedings of the Second International Symposium
on Peritoneal Dialysis

Berlin (-West), June 16-19, 1981

ADVANCES IN PERITONEAL DIALYSIS

Editors: G. M. Gahl

M. Kessel

K. D. Nolph



一九八四年十月十四日

Advances in peritoneal dialysis

*Proceedings of the Second International Symposium
on Peritoneal Dialysis
Berlin (-West), June 16-19, 1981*

Editors:

G.M. Gahl

M. Kessel

K.D. Nolph



一九八一年四月十四日



1981

Excerpta Medica, Amsterdam — Oxford — Princeton

©Excerpta Medica 1981

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

International Congress Series No. 567

ISBN Excerpta Medica 90 219 9537 9

ISBN Elsevier North-Holland 0 444 90232 5

Library of Congress Cataloging in Publication Data

Main entry under title:

Advances in Peritoneal Dialysis

Proceedings of the Second International Symposium on

Peritoneal Dialysis

Berlin (-West), June 16-19, 1981

(International Congress Series No. 567)

Includes Bibliographies.

Includes Indexes.

1. Peritoneal dialysis--Congresses. 2. Ambulatory medical
care--Congresses. I. Gahl, G. (Gerhard) M., 1938- . II.

Kessel, M. (Michael). III. Nolph, Karl D. IV. Series. [DMLM:

1. Peritoneal dialysis--Congresses. 2. Ambulatory care--Congresses.

W3 EX89 no. 567 1981 / WJ 378 C762 1981.]

RC901.7.P47C66

617'.461059

81-12516

ISBN 0-444-90232-5 (Elsevier-North Holland) AACR2

Publisher:

Excerpta Medica

305 Keizersgracht

1000 BC Amsterdam

P.O. Box 1126

Sole distributors for the USA and Canada:

Elsevier North-Holland Inc.

52 Vanderbilt Avenue

New York, NY 10017

Printed in The Netherlands by Casparie Amsterdam

PREFACE

At the present time interest in peritoneal dialysis is growing fast. Therefore, in order to ensure rapid publication it was decided to publish the Proceedings of the Second International Symposium on Peritoneal Dialysis, held in Berlin (-West), June 16–19, 1981, in a camera-ready form. We feel very much indebted to all authors for submitting their manuscripts at the time of the meeting, or even earlier, and for their adherence to the instructions to authors, thus making the basis for a speedy publication. However, our goal would not have been achieved without the close cooperation and valuable support from Excerpta Medica.

Thus, with a few exceptions, all presentations could be included in the Proceedings. Unfortunately lack of space and limited funds required the omission of the nursing sessions and the discussions, although many valuable comments were made. In order to facilitate reading of the Proceedings, oral presentations and poster presentations dealing with the same main topic are grouped together, indicating the important role of the poster presentations.

We would like to extend our thanks to Travenol who so generously supported the Symposium and made this publication possible.

May this publication serve to further develop peritoneal dialysis and define its role for treatment of patients with renal failure.

August 1981 G.M. Gahl, M. Kessel

Department of Internal Medicine and Nephrology, Klinikum
Charlottenburg, Freie Universität Berlin, Berlin (-West),
Germany

and K.D. Nolph

Division of Nephrology, Department of Medicine, Harry S. Truman
Memorial Veterans Hospital and University of Missouri Health
Sciences Center, Columbia, MO, U.S.A.

INTRODUCTORY REMARKS

G.M. Gahl

Department of Nephrology, Klinikum Charlottenburg, Freie Universität Berlin, Berlin (-West), Germany

During the last two years a tremendous number of local, national and international meetings devoted to peritoneal dialysis have been organized. With this in mind I asked myself, whether we really needed this Second International Symposium on Peritoneal Dialysis. However, three months ago, when the deadline for the submission of abstracts had passed, my doubts dissipated: the great interest in this Symposium was clearly reflected in the number of abstracts (154) received for consideration, and by the fact that approximately 500 active participants from 41 different countries registered in advance.

Although I have always stressed that this Conference is not a CAPD Symposium, it is interesting to note that among the 154 abstracts submitted all but 25 deal with continuous ambulatory peritoneal dialysis (CAPD). This emphasizes the importance of this relatively new form of treatment at the present time.

As you can imagine it was difficult, with such a large number of abstracts, to set up the programme for this Symposium. This was particularly true as it was felt that parallel sessions should be avoided at such a relatively small Symposium, at least at this stage in the development of peritoneal dialysis. Therefore, we were forced to reject some papers among which were several of very high quality. The five members of the Scientific Committee who reviewed all the abstracts had to keep in mind the overall programme, which was to present a comprehensive and up to date summary of peritoneal dialysis. Therefore, we should not grumble and attack the programme committee too strongly but should remember that the first abstract ever dealing with CAPD (although the term had not been coined at the time) was rejected by the American Society of Artificial Internal Organs in 1976.

I am particularly happy about the decision to include in the programme a parallel nursing session, which was organized by Mrs. Barbara Prowant from Columbia, Missouri. I feel that this aspect is of major importance today, because worldwide more and more centres are developing peritoneal dialysis programmes, where nurses play key roles. The technical exhibition forms another essential part of the Symposium, informing us of the present state of technical development.

Although we will be talking mostly about peritoneal dialysis during the next few days, I do hope that a critical audience and lively discussions will help destroy the notion that we rely solely on this method, but that we regard peritoneal dialysis as one of our possible approaches for patients with end-stage renal disease. I do believe that we will have an excellent and stimulating meeting, which I hope will answer most of the questions that emerged from the First International Symposium on Peritoneal Dialysis which was held in Mexico three years ago.

I am very much indebted to the Sponsors of this Symposium: the International Society of Nephrology, the Deutsche Forschungsgemeinschaft, the Freie Universität Berlin, the Senat of Berlin and the Industry, for their generous support. Their help cannot be over-emphasized.

Finally I would like to thank the Executive Committee for bringing the Symposium to Berlin, and thus giving me the chance to host this meeting. On behalf of the Executive, the Scientific and the Local Organizing Committees, I welcome all of you to Berlin, and I hope that you will find the Symposium interesting and rewarding.

Although I have always stressed that this Symposium is not a CAPD Symposium, it is interesting to note that among the 134 abstracts submitted all but 33 deal with continuous ambulatory peritoneal dialysis (CAPD). This emphasizes the importance of this relatively new form of treatment at the present time. As you can imagine it was difficult, with such a large number of abstracts, to set up the programme for this Symposium. This was particularly true as it was felt that parallel sessions should be avoided as such a relatively small Symposium as this should be avoided as the development of peritoneal dialysis. Therefore, we were forced to reject some papers among which were several of very high quality. The five members of the Scientific Committee who reviewed all the abstracts had to keep in mind the overall programme, which was to present a comprehensive and up to date summary of peritoneal dialysis. Therefore, we would not include and attack the programme Committee too strongly but should remember that the first abstract ever dealing with CAPD (although the term had not been coined at the time) was rejected by the American Society of Artificial Internal Organs in 1976. I am particularly happy about the decision to include in the programme a parallel nursing session, which was organized by Mrs Barbara Brown from Columbia, Missouri. I feel that this aspect is of major importance today, because worldwide more and more centres are developing peritoneal dialysis programmes, where nurses play key roles. The technical exhibition forms another essential part of the Symposium. Informing us of the present state of technical development. Although we will be talking mostly about peritoneal dialysis during the next few days, I do hope that a critical audience and lively discussions will help destroy the notion that we rely solely on this method, but that we regard peritoneal dialysis as one of our possible approaches for patients with end-stage renal disease. I do believe that we will have an excellent and stimulating meeting, which I hope will answer most of the questions that emerged from the First International Symposium on Peritoneal Dialysis which was held in Mexico three years ago.

INTRODUCTORY REMARKS

Dr. Alejandro Treviño Becerra, Chief of the Nephrology Department, Hospital de Especialidades, Centro Médico "La Raza", IMSS, México 15, D.F., MEXICO.



During the last three years peritoneal dialysis (PD) has been firmly established, Specially Continous Ambulatory Peritoneal Dialysis (CAPD) and other mechanical methods that have improved the efficiency as well as the safety of this procedure. As a result, an increasing interest has been observed that can be inferred from the following data; The First International Symposium on Peritoneal Dialysis held in Chapala, México, registered 150 participants; 44 free papers were presented and 4 stands in the exhibition in Berlin these figures have increased more than threefold.

Three years ago in Chapala an outstanding review was made of the basic concepts of the intracorporeal dialysis treatments, showing also different implements and modifications (1). Today PD is not more as a third class treatment; rather, as a first class treatment and in some aspects even better than hemodialysis. Five books have been published, about those subjects, no less than 200 papers and a quarterly bulletin of PD appears in the literature. Research and the aspects concerning care and cost for the patient have been highly productive as can be seen by the constantly increasing numbers of patients on PD and CAPD. In June 1978 just two countries had this treatment available with only 24 patients; Already there are patients who had been on CAPD for 4 years. At present at least 7500 patients in 60 countries throughout the world are being treated by CAPD. If we compare CAPD with extracorporeal dialysis, renal trasplantation, hemoperfusion, we can see that CAPD has had a more significant increase. We know the great impact of CAPD in Canada, Italy and Great Britain, countries where a high percentage of uremic patients are now in PD and also countries like Bangladesh who has 6 patients on CAPD of the population of 7 on dialysis.

Costs have remained not very high but it is estimated that the first year for a patient on CAPD will cost aproximatly \$14,000 (U.S. currency) the following years cost less, roughly \$11,000 and according to data

from Moncrief, approximately \$1,200 monthly.

During this Symposium much will be said about morphology, Physiology, peritoneal kinetics, nutritional and metabolic factors of patients on CAPD, problems of diabetes, renal bone disease, anemia, cardiovascular, nervous system functions and peritonitis in patients on PD Catheters will be another topic of discussion. We will hear, no doubt, that the interrogations from 1978 have already been clarified concerning protein supplement, balance of fluid, and blood pressure control but there are still old problems to solve and of course new ones.

Nephrology that has revolutionized medicine introducing artificial kidneys, renal transplantation and blood exvivo perfusion is now making another significant contribution with the advent of peritoneal route that had been used for administration of insulin, total nutrition, etc. Now is feasible that partial substitution of an Organ by another apparently foreign, for example terminal kidney for healthy peritoneal capillaries. A layman observing the dialysate that has been in the peritoneal cavity for 4 or 6 hours will think this fluid has the aspect of urine, that is, the peritoneum is producing urine, but is a bad quality urine.

We do not know yet if endocrine renal function can be substituted by the peritoneal splanchnic capillaries; nor are we certain that this membrane can substitute the tubular, interstitial and macular function of the healthy kidney. From this it can be inferred, that chronic renal failure patients should be on CAPD when they still have residual endocrine function. CAPD and CCPD supports the theory that uremic syndrome is due to the accumulation of endogenous toxic substance, together with metabolites product of drug accumulation, and malnutrition as well. This doesn't happens in CAPD patients, the peritoneum removes substances with different molecular weights, detoxifying the patient who is not on high doses of multiple drugs; and lastly the patient eats better and is not malnourished.

After reviewing the significant progress attained in the area of PD we can conclude that this therapeutic modality has competed with it and now is parallel to extracorporeal dialysis, but I do not think it is honest to expect CAPD to solve the problem of chronic uremia if the artificial kidney has not been able to do (Table I).

TABLE I.- COMPARATIVE FACTORS BETWEEN EXTRACORPOREAL DIALYSIS AND CAPD

	KIDNEY MACHINE	CAPD
AGE	(1943) 38 Years	(1975) 6 Years
CLEARANCE * (ml/min)		
Urea	135	84
B-12	30	53
Inulina	5	39
HOURS OF TREATMENT A WEEK	9 to 18	144 to 168
LITRES OF FLUID A WEEK	360	54
COST IN U.S. DOLLARS FOR A YEAR	12,500 to 23,000	11,000 to 14,000
HEMATOCRIT		
BLOOD PRESSURE		
PARATHORMONE		
ADVERSE EFFECTS	MULTIFACTORIAL HAEMODIALYTIC SYNDROME (**) STEADY	LOCAL COMPLAINTS PERITONITIS HYPERTRIGLYCERIDEMIA CONTINUOUSLY
TECHNICAL IMPROVE		

* Popovich 17 Cont. to Nephrology, 1979 (Basel)

** Treviño B.: Rev. Med. IMSS, 1981 (México).

In our patients, biochemical control obtained with CAPD are better than those obtained with hemodialysis. This results is more favourable economic and psychological conditions and less labour problems for chronic renal failure patients on CAPD; this is what are describing in a of this book (2) where we stress that CAPD is for us the only therapeutic modality for uremic outpatients. We do not think that peritonitis per se avoid treatment with PD. Metabolic complications can occur such as hypertriglyceridemia that remains unexplainable (3).

It is possible that when this meeting is adjourned we will be able to know if we are now closer to the ideal intracorporeal dialysis or what steps must be taken to achieve this objective (Table II). Among other things availability of safer catheter connexions, an ideal formula for the peritoneal dialysis solution and very important finally not inflation the cost and widespread the information. The community of scientific working on PD we must help the peritoneum membrane to produce real urine, without any risk.

TABLE II.- FUTURE OF INTRACORPOREAL DIALYSIS

- SAFER CATHETER CONNEXIONS
- IDEAL PERITONEAL SOLUTION FORMULA
- BETTER ACCESS TO ABDOMINAL CAVITY
 - NATURAL ORIFICES OR VASCULAR IMPLANT
- CUT COSTS AND WIDESPREAD INFORMATION

REFERENCES

- 1.- Contr. Nephrol. Vol. 17, (Karger, Basel 1979)
- 2.- Treviño, B.A.; Embessd, M.L; Zuñiga, V; et al
Four factors in the evolution on patients in different types of dialysis. Publish in this volumen.
- 3.- Treviño B.A.; Monteon, F; Toledo, M; Aviles, C;
Hypertriglyceridemia in patients on continous ambulatory peritoneal dialysis. Publish in this volumen.

CONTENTS

Preface

G.M. Gahl, M. Kessel and K.D. Nolph

xiii

Introductory remarks

G.M. Gahl

xv

A. Treviño Becerra

xvii

Session I. Morphology, physiology

Chairmen: K.D. Nolph and Z. Twardowski

Introductory remarks: Advances in peritoneal transport physiology –

K.D. Nolph

3

Basal permeability of the peritoneal membrane during continuous ambulatory peritoneal dialysis (CAPD) – *B. Rippe, G. Stelin and J. Ahlmén*

5

Peritoneal structure alterations on CAPD – *C. Verger, O. Brunschvicg, Y. Le Charpentier, A. Lavergne and J. Vantelon*

10

The evidence of selective migration of polymorphonuclear neutrophils (PMN) into peritoneal fluid during maintenance peritoneal dialysis (MPD) – *H. Wysocki, R. Czarnecki, B. Wierusz-Wysocka, G. Michta, K. Wysocki and K. Bączyk*

16

Clinical experience with a dog model to investigate continuous ambulatory peritoneal dialysis – *R.P. Popovich, M.P. Hiatt, W.K. Pyle, E.E. Simmons and J.W. Moncrief*

21

Ultrastructure of the rabbit mesentery – *L. Gotloib, S. Rabinovich, H. Rodella, A. Medline and D.G. Oreopoulos*

27

Poster

Studies on function of rat parietal peritoneal mesothelium under different conditions in in-vitro experiments – *M. Simon, J. Knapowski, E. Feder, G. Wiedner and W. Skorupski*

32

Session II. Kinetics, efficiency

Chairmen: J.F. Maher and P.C. Farrell

Introductory remarks: Transport kinetics of drugs and peritoneal dialysis – *J.F. Maher*

37

Mass transfer in peritoneal dialysis – *W.K. Pyle, R.P. Popovich and J.W. Moncrief*

41

Middle molecules in chronic uremic patients treated with peritoneal dialysis – *J. Bergström, H. Asaba, P. Fürst and B. Lindholm*

47

Middle molecular substances in peritoneal dialysis fluids of uremic patients – <i>A. Saito, T.G. Chung, T. Niwa, K. Maeda and K. Kobayashi</i>	54
Middle molecule b 4–2 removal rate in patients on continuous ambulatory peritoneal dialysis – <i>N.K. Man, C. Verger, P. Faguer, J. Vantelon and J.L. Funck-Brentano</i>	60
Prostaglandin effects on peritoneal transport – <i>J.F. Maher, P. Hirszel and M. Lasrich</i>	65

Posters

The effect of peritoneal dialysis on serum folic acid binding capacity – <i>N. Papadoyanakis, P. Ziroyanis, E. Papathanasiou, V. Alevizou, M. Kesse- Elias, E. Gyftaki and S. Mouloupoulos</i>	70
Calcium transfer during intermittent peritoneal dialysis – <i>K.E. Hemmeløff Andersen and F.B. Pedersen</i>	73
Serum and dialysate middle molecules behaviour of uremic patients in CAPD, IPD and RDT therapy – <i>S. Carozzi, D. Trasforini, S. Lamperi, M. Cozzari and U. Buoncristiani</i>	76
A study on the excretion of uremic toxins during continuous ambulatory peritoneal dialysis (CAPD) – <i>K. Isoda, R. Nakazawa, H. Shishido, T. Hachisu, K. Tahara, M. Yatanabe and Y. Kimura</i>	79
Significance of the sequential intraperitoneal administration of nitroprusside in intermittent peritoneal dialysis – <i>E. Rimbau, J. Lloveras, M.A. Orfila, J. Aubia, J. Masramon and M. Llorach</i>	82
Pharmacokinetics of digoxin in CAPD – <i>E. De Paoli Vitali, D. Casol, C. Tessarin, G.F. Tisoni and R. Cavagna</i>	85
Pharmacokinetics of digoxin and digitoxin in patients on continuous ambula- tory peritoneal dialysis (CAPD) – <i>T. Risler, U. Peters, J. Paßlick, B. Grabensee and J. Krokou</i>	88
Pharmacokinetics of furosemide in CAPD – <i>H.F. Boutron, J.F. Brocard, E. Singlas, B. Charpentier and D. Fries</i>	90
Furosemide induced discrepancy between peritoneal clearance of uric acid and potassium in terminal uraemia – <i>A. Grzegorzewska and K. Bączyk</i>	93
Cefotaxim pharmacokinetics in peritoneal dialysis (PD) – <i>R. Schurig, D. Kampf, W. Spießner, K. Weihermüller and H. Becker</i>	96
Peritoneal pharmacokinetics of gentamicin in man and rabbit – <i>M. De Paepe, N. Lameire, S. Ringoir, F. Belpaire and M. Bogaert</i>	99

Session III. Clinical experience with different techniques; catheters

Chairmen: R.P. Popovich and M. Kessel

A new system for continuous ambulatory peritoneal dialysis (CAPD) – <i>N. Di Paolo, U. Buoncristiani, C. Frigato, M. De Mia and M. Rubegni</i>	105
---	-----

Efficiency of continuous ambulatory peritoneal dialysis (CAPD) with three 2.5 l exchanges per day – Z. Twardowski, L. Janicka, M. Majdan, E. Bocheńska-Nowacka and W. Pawlin	111
A comparison of four versus three exchanges per day with continuous ambulatory peritoneal dialysis – J.W. Moncrief and R.P. Popovich	116
Continuous equilibration peritoneal dialysis (CEPD) versus acute peritoneal dialysis (APD) – A. Katirtzoglou, G. Digenis, D. Mayopoulou-Symvoulidis, D. Zervakis, A. Symvoulidis and Z. Komninos	122
Continuous cyclic peritoneal dialysis – J.A. Diaz-Buxo, P.J. Walker, J.T. Chandler, C.D. Farmer, K.L. Holt and P. Cox	126
Comparison of CAPD with HD and IPD – P.C. Farrell and D.H. Randerson	131

Posters

Home intermittent peritoneal dialysis in high risk patients – M. Goldberg, K.B. Baugham and D.G. Wombolt	138
CCPD – an improvement on CAPD – J. Walls, B.A. Smith, J. Feehally, D. Taverner and C. Turgan	141
Advantages of using double-bag system on CAPD patients – G. Bazzato, S. Landini, U. Coli, S. Lucatello, A. Fracasso, P. Morachiello, F. Righetto and R. Michieli	144
Clinical-metabolic comparison of three different schedules of equilibrium peritoneal dialysis – U. Buoncristiani, N. Di Paolo, M. Cozzari, L. Lorusso, G. Quintaliani, I. Zampi and R. Ciccone	147
Intermittent peritoneal dialysis (IPD) versus continuous ambulatory peritoneal dialysis (CAPD): a retrospective experience in one center – J.C. Sabatier, R. Gonthier, J. Toulon, B. Laurent, J. Juge, C. Genin and F.C. Berthoux	151
IPD and CAPD: experience with a group of patients with both sequential treatments – V. Mioli, P. Pacchiarotti, R. Tarchini, M. Santini and S. Figus	155
Large volume filtration of peritoneal fluid in intermittent or continuous ambulatory peritoneal dialysis – F. Stec, A. Slingeneyer, C. Perez, E. Despaux and C. Mion	158
Do hemofiltration and CAPD have a role in chronic uremia? – G. Piccoli, S. Alloati, F. Quarello, G. Bosticardo, F. Giacchino, P. Belardi, G. Triolo, G. Castagneri and A. Vercellone	164
A double-chamber catheter for chronic ambulatory peritoneal dialysis (CAPD) – V. Calderaro, B. Memoli, A. Caputo, E. Di Salvo and V.E. Andreucci	167
Subcutaneous peritoneal access device used for intraperitoneal insulin treatment of non-uraemic diabetic patients – C. Kablitz, R.L. Stephen, J.J. Harrow, J.A. Nelson, F.H. Tyler, B.K. Hanover and S.C. Jacobsen	170
The stylet indwelling peritoneal catheter “Braun” – H. Thieler, U. Schmidt, N. Jung and G. Korten	173

Experience with Repl-A-Cath interchangeable peritoneal catheter – <i>R. Cavagna, D. Casol, E. De Paoli Vitali, C. Tessarin, P. Riegler, W. Huber, G. Bandiani, E. Camaiora, M.A. Nicolini and V. Perotta</i>	176
Is an alternative to the Tenckhoff catheter necessary? – <i>A. Slingeneyer, C. Mion, A. Charpiat and M. Balmes</i>	179
Straight or curled Tenckhoff peritoneal catheter for continuous ambulatory peritoneal dialysis? – <i>J. Rottembourg, D. Jacq, A. Agrafiotis, A. Balducci, A. Krouiri, Y. El Shahat and B. Issad</i>	185

Session IV. Miscellaneous clinical aspects

Chairmen: K. Kobayashi and J.W. Moncrief

Three years experience with continuous ambulatory peritoneal dialysis (CAPD) – <i>R. Khanna, D.G. Oreopoulos, N. Dombros, S. Vas, P. Williams, H.E. Meema, H. Husdan, R. Ogilvie, G. Zellerman, D.A.K. Roncari, S. Clayton and S. Izatt</i>	191
Adaptation to CAPD: psychological factors – <i>H.J. Burton, J. Conley, R.M. Lindsay, L. Wai and J.M. Richmond</i>	196
Nineteen months' experience with continuous ambulatory peritoneal dialysis (CAPD) in children: main clinical and biological results – <i>M. Guillot, M.-J. Clermont, M.-F. Gagnadoux and M. Broyer</i>	203
Failure of the peritoneal membrane during chronic intermittent peritoneal dialysis – <i>R. Backenroth-Maayan, R. Longnecker and D. Kambosos</i>	208
Continuous ambulatory peritoneal dialysis and cellular immunity – <i>F. Giacchino, S. Alloatti, P. Belardi, F. Quarello, G.M. Bosticardo, M. Pozzato, A. Aprato, G. Segoloni and G. Piccoli</i>	214
Middle and low molecular weight (MLMW) substances in patients treated with continuous ambulatory peritoneal dialysis (CAPD) – <i>A. Locatelli, A. Nesse, E. Arrizurieta, L. De Benedetti, E. Chaya, C. Marelli and R. Paparone</i>	220
Loss of ultrafiltration in continuous ambulatory peritoneal dialysis: clinical data – <i>B. Faller and J.F. Marichal</i>	227

Posters

Continuous ambulatory peritoneal dialysis: one year's experience of a cooperative study in Japan – <i>Y. Kawaguchi, K. Ota, S. Nakagawa, T. Fujinaga and S. Fujimi</i>	233
Subjective assessment of CAPD patients – <i>D.H. Randerson and P.C. Farrell</i>	236
Four factors (D) in the evolution of patients in different types of dialysis – <i>A. Treviño Becerra, L. Erbesd, J. Velázquez, V. Zuñiga, H. Velázquez, J.J. Sánchez Becerril, B. Vázquez and F. Monteón</i>	240
Some aspects of gastrointestinal function in CAPD – <i>N. Di Paolo, U. Buoncristiani, A. Sorrentino, F. Strappaveccia, E. Gaggiotti and M. Rubegni</i>	244

Beta-2 microglobulin in haemodialysis and continuous ambulatory peritoneal dialysis – <i>J. Feehally, F. Baker and J. Walls</i>	250
Acute renal failure treatment by continuous peritoneal dialysis (CPD) – <i>J.C. Sabatier, R. Gonthier, B. Laurent, J. Toulon, C. Genin and F.C. Berthoux</i>	253
Continuous peritoneal dialysis (CPD) as treatment of acute renal failure in early childhood – <i>R. Schurig, H. Paust, G.M. Gahl, H. Becker and W. Park</i>	256

Session V. Peritonitis

Chairmen: D.G. Oreopoulos and C. Mion

Introductory remarks: Peritonitis in patients on CAPD – <i>D.G. Oreopoulos, R. Khanna and S.I. Vas</i>	261
Analysis of peritonitis data in CAPD – <i>D.H. Randerson and P.C. Farrell</i>	265
Analysis of peritonitis incidence in CAPD patients – <i>F. Villarreal</i>	270
Eosinophilic peritonitis – <i>B.S. Spinowitz, R.A. Golden, J.H. Rascoff and C. Charytan</i>	276
Reason for failure of saline-iodine flushes – <i>K.I. Furman, H. Kündig, D.T. Ninin and J.D. Block</i>	281
Changes in water removal due to peritonitis during continuous peritoneal dialysis – <i>L.C. Smeby, T.-E. Widerøe, T.M. Svartås and S. Jørstad</i>	287

Posters

Comparison of methods for early detection of peritonitis in patients on chronic ambulatory peritoneal dialysis – <i>N.P. Vites, B.A.F. Dale, G. Grice, D.M. Jones, A.J. Ralston and P. Ackrill</i>	293
Fibrin coating of the peritoneal catheter as a cause of recurrent peritonitis – <i>B. Schuenemann, P. Schwartz, H. Mergerian, E. Quellhorst, C. Fuchs, J. Rieger and F. Scheler</i>	296
Incidence of sterile peritonitis in CAPD – <i>K. Záruba and M. Oliveri</i>	299
PD peritonitis: course dependence on bacterial species – <i>E.S. Kraus and D.A. Spector</i>	302
The leukocyte count and acute peritonitis in intermittent peritoneal dialysis patients – <i>F. Joglar, M. Tort, R. Burgos and V. Martínez</i>	305

Session VI. Anaemia, cardiopulmonary function, nervous system

Chairmen: A. Treviño Becerra and J. Bergström

Erythropoietin behaviour and renal anemia in CAPD – <i>S. Lamperi, A. Icardi, S. Carozzi and D. Trasforini</i>	311
Evolution of red cell mass and hematocrit readings in patients on continuous ambulatory peritoneal dialysis – <i>M. De Paepe, N. Lameire, K. Schelstraete and S. Ringoir</i>	317

Influence of changes in dialysate composition on plasma electrolytes and incidence of hypotension in continuous ambulatory peritoneal dialysis – <i>N. Lameire, M. De Paepe and S. Ringoir</i>	322
Altered pulmonary function with continuous ambulatory peritoneal dialysis (CAPD) – <i>J.F. Winchester, A.M.T. Da Silva, W. Davis, C. Weir, W. Barnard, T.A. Rakowski and G.E. Schreiner</i>	329
Influence of continuous ambulatory peritoneal dialysis (CAPD) on autonomic nervous system – <i>P. Zucchelli, C. Chiarini, E. Degli Esposti, L. Fabbri, A. Santoro, A. Sturani and A. Zuccalà</i>	335
Nerve electrophysiological parameters in patients undergoing CAPD over two years – <i>A. Pierratos, R.D.G. Blair, R. Khanna, C. Quinton and D.G. Oreopoulos</i>	341

Posters

Improvement of anemia under continuous ambulatory peritoneal dialysis (CAPD) in comparison to intermittent peritoneal dialysis (IPD) – <i>H. Becker, B.M. Bombik, R. Schurig, G.M. Gahl, A. Pustelnik and M. Kessel</i>	347
Uremic toxicity and erythropoietin during continuous ambulatory peritoneal dialysis – <i>T.-E. Widerøe, T. Sanengen, L.C. Smeby, S. Halvorsen and S. Jørstad</i>	350
Haemodynamic studies in patients on CAPD with double-bag system. Preliminary data – <i>G. Bazzato, U. Coli, S. Landini, R. De Stefani, A. Milanese, G.P. Pinato and P. Wolf</i>	353
Pulmonary function tests in patients on continuous ambulatory peritoneal dialysis – <i>S. Singh, A. Dale, B. Morgan and H. Sahebjani</i>	356
Effects on brain tissue of peritoneal dialysis: CAPD versus IPD – <i>G. La Greca, P. Dettori, S. Biasioli, S. Chiaramonte, A. Fabris, M. Feriani, V. Pinna, E. Pisani and C. Ronco</i>	359

Session VII. Diabetes

Chairmen: M. Legrain and N.M. Thomson

Introductory remarks: Continuous ambulatory peritoneal dialysis (CAPD) versus other treatment modalities in end-stage diabetic nephropathy – <i>M. Legrain, Y. El Shahat, J. Rottembourg, A. Balducci and C. Jacobs</i>	365
Intraperitoneal (¹²⁵ I) insulin absorption during intermittent and continuous peritoneal dialysis – <i>T.-E. Widerøe, L.C. Smeby, K.J. Berg, S. Jørstad and T.M. Svartås</i>	369
Influence of different modes of treatment on the complications of diabetes mellitus – <i>E. Quellhorst, B. Schuenemann and G. Mietzsch</i>	371
Home intermittent (IPD) and continuous ambulatory peritoneal dialysis (CAPD) as a long term treatment of end stage renal failure in diabetics – <i>A. Slingeneyer, C. Mion and J.L. Selam</i>	378

Session VIII. Metabolic aspects and nutrition

Chairmen: *M.J. Blumenkrantz and N.G. De Santo*

Introductory remarks: Studies of protein and nitrogen metabolism during continuous ambulatory peritoneal dialysis – <i>M.J. Blumenkrantz</i>	391
Nitrogen balance and growth in children on CAPD – <i>N.G. De Santo, G. Capodicasa, M. Pluvio, G. Gilli and C. Giordano</i>	397
Protein intake can be estimated from BUN with CAPD – <i>K.D. Nolph, M.I. Sarkin, B. Prowant and H. Moore</i>	405
Unexpected alteration of nutritional habits in patients undergoing CAPD – <i>H. v. Baeyer, G.M. Gahl, H. Riedinger, B. Borowzak and M. Kessel</i>	408
Glucose metabolism in patients on continuous ambulatory peritoneal dialysis (CAPD) – <i>B. Lindholm, J. Bergström and S.-G. Karlander</i>	413
Effect of continuous ambulatory peritoneal dialysis (CAPD) on lipid metabolism – <i>C. Turgan, J. Feehally, S. Bennett, T.J. Davies and J. Walls</i>	417

Posters

Effect of dialysate glucose load on plasma glucose and insulin levels in CAPD patients – <i>V.W. Armstrong, C. Fuchs and F. Scheler</i>	421
CAPD with intrabag insulin administration (IBIA): an easy strategy to improve the uremic diabetic patient (UDP) management – <i>G. Triolo, G. Segoloni, Q. Carta, D. Boggio-Bertinet, S. Alloatti, P. Stratta, M. Messina, G. Priasca and A. Vercellone</i>	424
Serum lipoprotein concentrations during continuous ambulatory peritoneal dialysis (CAPD) – <i>G. Keusch, F. Bammatter, R. Mordasini and U. Binswanger</i>	427
Hyperlipidaemia in patients on continuous ambulatory peritoneal dialysis – <i>R. Gokal, J.M. Ramos, J.G. McGurk, M.K. Ward and D.N.S. Kerr</i>	430
Lipoprotein (LP) metabolism in patients on continuous ambulatory peritoneal dialysis (CAPD) – <i>B. Lindholm, J. Bergström and H.-E. Norbeck</i>	434
Hypertriglyceridemia in patients on continuous ambulatory peritoneal dialysis – <i>F. Monteón, A. Treviño Becerra, D. González, M. Toledo, C. Aviles, A. Navarro, L. Aragón, F. Acuña and O. Scott</i>	437
Carnitine depletion with CAPD – <i>U. Buoncristiani, N. Di Paolo, C. Carobi, M. Cozzari, G. Quintaliani and R. Bracaglia</i>	441
Metabolic tolerance of continuous ambulatory peritoneal dialysis (CAPD) – <i>J.F. de Fremont, P. Bataille, P. Morinière, P. Kaczmareck, P. Fievet and A. Fournier</i>	446
Metabolic aspects of CAPD – <i>G. Splendiani, S. Acitelli, V. Albano, A. Gianforte and M. Tancredi</i>	449